provid
evid
cleav
pyr
pyr
cleavag
product
express
human
cardiovascular
tissu
demonstr
biolog
activ
pyr
human
rodent
apelin
receptor
vitro
vivo
data
show
report
enhanc
activ
cardiovascular
diseas
significantli
compromis
benefici
effect
apelin
base
therapi
exampl
pah
aim
apelin
predict
substrat
novel
therapeut
target
aim
demonstr
endogen
presenc
put
product
pyr
human
cardiovascular
tissu
confirm
retain
signific
biolog
activ
apelin
receptor
vitro
vivo
minimum
activ
apelin
fragment
also
investig
method
result
pyr
incub
recombin
human
result
de
novo
gener
pyr
identifi
mass
spectrometri
endogen
pyr
detect
immunostain
human
heart
lung
local
endothelium
express
undetect
lung
patient
pulmonari
arteri
hypertens
human
heart
pyr
pk
pk
compet
bind
nanomolar
affin
lower
pyr
pk
wherea
exhibit
highest
affin
pk
rank
order
potenc
peptid
inhibit
forskolinstimul
camp
pd
pyr
pd
pd
pyr
pd
truncat
peptid
retain
nanomolar
potenc
pd
shorter
fragment
exhibit
low
micromolar
potenc
recruit
assay
rank
order
potenc
pd
pyr
pd
pd
pd
pyr
pd
shorter
fragment
pd
pyr
contract
human
saphen
vein
similar
subnanomolar
potenc
pyr
potent
inotrop
pace
mous
right
ventricl
human
atria
pyr
elicit
dosedepend
decreas
blood
pressur
anesthet
rat
dosedepend
increas
forearm
blood
flow
human
volunt
apelin
famili
peptid
activ
apelin
receptor
also
known
apj
emerg
import
physiolog
pathophysiolog
cardiovascular
system
apelin
peptid
present
human
vascular
cardiac
endotheli
cell
kleinz
davenport
plasma
pyr
identifi
abund
cardiovascular
isoform
maguir
et
al
zhen
et
al
apelin
mediat
three
major
action
vitro
interact
apelin
receptor
cardiac
myocyt
caus
increas
cardiac
contractil
inotrop
action
apelin
order
magnitud
potent
vessel
intact
endothelium
apelin
act
releas
vasodil
may
oppos
action
vasoconstrictor
also
shown
remov
endothelium
unmask
constrictor
respons
mediat
apelin
receptor
present
vascular
smooth
muscl
maguir
et
al
importantli
healthi
volunt
heart
failur
patient
major
effect
apelin
infus
forearm
vivo
nitric
oxid
depend
arteri
dilat
japp
et
al
japp
et
al
barn
et
al
brame
et
al
heart
failur
patient
intracoronari
pyr
caus
coronari
vasodilat
increas
cardiac
contractil
japp
et
al
barn
et
al
system
infus
pyr
volunt
patient
increas
cardiac
index
lower
mean
arteri
blood
pressur
peripher
vascular
resist
japp
et
al
barn
et
al
apelin
downregul
pulmonari
arteri
hypertens
pah
devast
diseas
character
vascular
remodel
result
progress
obliter
pulmonari
circul
lead
right
ventricl
rv
hypertrophi
right
heart
failur
alastalo
et
al
chandra
et
al
therefor
apelin
receptor
may
repres
novel
target
futur
drug
develop
human
angiotensin
convert
enzym
sequenc
similar
ctermin
dipeptidylpeptidas
ace
donoghu
et
al
tipni
et
al
express
exampl
heart
kidney
lung
donoghu
et
al
ham
et
al
implic
patholog
condit
heart
failur
upregul
zisman
et
al
goulter
et
al
major
role
degrad
angiotensin
ii
angiotensin
act
benefici
vasodil
antiprolifer
agent
counterbalanc
action
vasoconstrictor
angiotensin
ii
santo
et
al
santo
et
al
also
viral
receptor
sever
acut
respiratori
syndrom
coronaviru
downregul
enzym
cell
surfac
result
angiotensin
iiinduc
lung
injuri
kuba
et
al
ration
develop
recombin
human
clinic
trial
acut
lung
injuri
haschk
et
al
interestingli
enhanc
activ
pharmacolog
gene
transfer
effect
prevent
revers
pah
shenoy
et
al
dai
et
al
benefici
action
thought
mediat
convers
angiotensin
ii
angiotensin
howev
possibl
interact
peptid
clear
screen
biolog
activ
peptid
report
two
other
hydrolyz
high
catalyt
effici
dynorphin
report
vasoact
result
remov
ctermin
phenylalanin
produc
metabolit
vicker
et
al
loss
termin
phenylalanin
apelin
assum
mechan
degrad
inactiv
peptid
aim
understand
impact
cleavag
reaction
apelin
signal
pathway
specif
object
firstli
confirm
pyr
figur
produc
hydrolysi
pyr
find
evid
pyr
endogen
peptid
determin
distribut
human
cardiovascular
tissu
secondli
demonstr
pyr
bind
apelin
receptor
activ
downstream
signal
pathway
cell
base
assay
thirdli
determin
pyr
retain
signific
biolog
activ
compar
figur
align
amino
acid
sequenc
apelin
peptid
hydrophob
amino
acid
shown
green
uncharg
polar
amino
acid
yellow
basic
amino
acid
blue
pyroglutam
red
frontier
neurosci
wwwfrontiersinorg
previous
report
data
maguir
et
al
brame
et
al
pyr
vitro
use
vascular
cardiac
human
rodent
tissu
system
infus
pyr
vivo
rat
final
sinc
predomin
action
apelin
infus
human
forearm
vasodilat
perform
firstinman
studi
pyr
explor
physiolog
action
peptid
healthi
volunt
also
wish
explor
structur
activ
relationship
sar
apelin
peptid
therefor
addit
experi
perform
ntermin
extend
put
endogen
peptid
alanin
substitut
shorter
fragment
figur
data
expand
knowledg
structur
activ
relationship
apelin
peptid
demonstr
signific
biolog
activ
metabolit
pyr
data
support
hypothesi
therapeut
strategi
enhanc
activ
upregul
cardiovascular
diseas
may
result
enhanc
breakdown
pyr
may
significantli
compromis
benefici
effect
endogen
apelin
signal
via
gener
pyr
human
tissu
sampl
obtain
inform
consent
papworth
hospit
research
tissu
bank
local
ethic
approv
synthesi
pyr
pyr
confirm
incub
pyr
nmol
enzym
pmol
gsk
ware
uk
buffer
ph
contain
nmorpholino
ethanesulfon
acid
me
mmoll
nacl
mmoll
zncl
h
c
follow
quench
ethylenediaminetetraacet
acid
edta
see
vicker
et
al
similar
protocol
reaction
mixtur
analyz
malditof
mass
spectrometri
sampl
desalt
use
millipor
usa
wash
acet
acid
elut
chca
matrix
aqueou
acetonitril
contain
trifluoroacet
acid
stainless
steel
sampl
slide
sampl
air
dri
analyz
use
water
maldi
micromx
timeofflight
mass
spectromet
usa
calibr
extern
use
polyethylen
glycol
hzlaser
power
threshold
spectra
sum
shot
collect
spiral
track
sampl
area
data
process
use
water
masslynx
softwar
usa
control
reaction
includ
incub
pyr
nmol
incub
pyr
nmol
pyr
nmol
without
incub
pmol
without
peptid
peroxidaseantiperoxidas
duallabel
immunofluoresc
stain
conduct
describ
kleinz
et
al
use
frozen
section
human
cardiomyopathi
heart
n
histolog
normal
n
pah
n
lung
affin
purifi
rabbitanti
pyr
antiserum
dilut
custom
synthes
antibodi
rais
relev
apelin
peptid
fragment
ckgpmp
lack
ctermin
phenylalanin
select
confirm
comparison
correspond
fragment
contain
ctermin
phenylalanin
ckgpmpf
elisa
figur
contrast
commerci
avail
antibodi
phoenix
pharmaceut
inc
ca
usa
cross
react
pyr
pyr
figur
r
system
mn
usa
abcam
cambridg
uk
antisera
also
use
von
willebrand
factor
vwf
dako
glostrup
denmark
use
endotheli
marker
peroxidas
stain
section
examin
bright
field
microscop
olympu
southendonsea
uk
imag
use
camera
celld
soft
imag
system
olympu
wherea
fluoresc
stain
imag
use
leica
scan
confoc
microscop
tc
leica
microsystem
milton
keyn
uk
imag
process
roll
ball
method
histogram
redistribut
appli
equal
entir
imag
channel
overlay
carri
use
imagej
assay
perform
human
heart
previous
describ
brame
et
al
briefli
homogen
human
left
ventricl
lv
incub
min
nmoll
glp
nle
tyr
assay
buffer
mmoll
tri
mgcl
ph
c
presenc
increas
concentr
pyr
pyr
sar
singl
concentr
nonspecif
bind
defin
use
pyr
equilibrium
broken
centrifug
g
min
c
pellet
wash
trishcl
buffer
mmoll
ph
c
recentrifug
pellet
count
detect
bound
radioact
competit
bind
data
analyz
use
graphpad
prism
graphpad
softwar
inc
la
jolla
ca
usa
obtain
valu
pk
neg
log
dissoci
constant
deriv
ic
compet
ligand
radioligand
concentr
radioligand
affin
cheng
prusoff
equat
experi
perform
triplic
inhibit
camp
accumul
recruit
receptor
intern
apelin
isoform
modifi
truncat
apelin
peptid
studi
use
cell
express
human
apelin
receptor
discoverx
ca
usa
per
manufactur
instruct
assay
result
chemiluminesc
signal
measur
rel
light
unit
rlu
use
lumilit
tm
micropl
reader
discoverx
fremont
ca
camp
assay
forskolin
use
stimul
camp
product
concentrationrespons
curv
construct
pyr
pyr
nmoll
agonist
respons
express
forskolin
respons
intern
assay
concentrationrespons
curv
construct
pyr
pyr
nmoll
agonist
respons
express
maximum
respons
pyr
data
analyz
use
logist
equat
use
graphpad
prism
determin
valu
potenc
pd
ec
ec
concentr
produc
half
maxim
respons
maximum
respons
e
max
nvalu
given
number
replicatesnumb
experi
use
data
camp
assay
predomin
cardiac
isoform
pyr
use
refer
ligand
rel
activ
g
proteindepend
independ
signal
pathway
pyr
pyr
compar
use
bia
analysi
describ
van
der
westhuizen
et
al
addit
assay
experi
perform
pyr
incub
describ
assay
control
concentrationrespons
curv
construct
pyr
pyr
compar
concentrationrespons
curv
construct
agonist
follow
preincub
vascular
smooth
muscl
apelin
receptormedi
contract
exploit
bioassay
compar
vitro
potenc
apelin
peptid
experi
carri
previous
describ
maguir
endotheliumdenud
saphen
vein
concentrationrespons
curv
construct
pyr
nmoll
agonist
respons
express
termin
respons
kcl
mmoll
inotrop
action
pyr
determin
mous
pace
rv
n
comparison
two
sampl
human
pace
atrial
appendag
strip
describ
maguir
et
al
data
express
termin
respons
cacl
data
vascular
cardiac
experi
analyz
use
logist
curv
graphpad
prism
determin
valu
pd
e
max
experi
perform
accord
local
ethic
committe
univers
colleg
london
home
offic
uk
guidelin
scientif
procedur
act
conform
direct
effect
system
infus
pyr
increment
bolu
dose
blood
pressur
heart
rate
stroke
volum
cardiac
output
assess
male
wistar
rat
g
bodi
weight
describ
brame
et
al
anesthet
isofluran
induct
mainten
continu
monitor
throughout
left
carotid
arteri
right
jugular
vein
cannul
mm
polyvinyl
chlorid
tube
mean
arteri
pressur
map
measur
throughout
procedur
via
pressur
transduc
powerlab
ad
instrument
chalgrov
uk
connect
arteri
line
baselin
hemodynam
record
use
chart
acquisit
softwar
channel
powerlab
system
ad
instrument
chalgrov
uk
min
stabil
period
thorac
echocardiographi
perform
scan
depth
cm
use
mhz
probe
vivid
dimens
ge
healthcar
bedford
uk
pulsedwav
doppler
use
determin
aortic
blood
flow
veloc
aortic
arch
stroke
volum
sv
determin
product
velocitytim
integr
vti
vessel
crosssect
area
data
six
consecut
cardiac
cycl
use
determin
heart
rate
hr
marker
left
ventricular
contractil
peak
veloc
pv
valu
sv
hr
use
calcul
cardiac
output
co
respir
rate
determin
movement
diaphragm
use
timemot
model
end
studi
rat
euthan
intraven
pentobarbiton
exsanguin
studi
perform
healthi
volunt
n
univers
cambridg
vascular
research
unit
addenbrook
hospit
cambridg
uk
volunt
characterist
given
tabl
studi
carri
accord
recommend
nation
research
ethic
servic
committe
east
englandcambridg
central
written
inform
consent
subject
subject
gave
written
inform
consent
accord
declar
helsinki
protocol
approv
nation
research
ethic
servic
committe
east
englandcambridg
central
rec
chang
forearm
blood
flow
fbf
respons
pyr
nmolmin
measur
previous
describ
brame
et
al
exclus
criteria
ischem
heart
diseas
respiratori
renal
neurolog
diseas
diabet
mellitu
hypertens
bmi
bmi
smoker
pregnant
use
vasoact
medic
nsaidsaspirin
within
h
studi
current
involv
research
studi
omron
oscillimetr
sphygmomanomet
use
measur
blood
pressur
heart
rate
baselin
everi
min
contralater
arm
period
cuff
around
upper
arm
inflat
mmhg
deflat
interrupt
venou
return
min
measur
hand
circul
exclud
inflat
wrist
cuff
mmhg
chang
forearm
volum
measur
mercuryinsilast
strain
gaug
fbf
subsequ
express
ml
forearm
volum
per
min
infus
peptid
via
cathet
portex
kent
uk
brachial
arteri
nondomin
arm
cannul
needl
cooper
needl
work
birmingham
uk
local
anesthesia
lignocain
hameln
pharmaceut
ltd
gloucest
uk
fbf
measur
arm
respons
pyr
present
absolut
chang
forearm
blood
flow
preinfus
baselin
valu
pyr
suppli
seal
glass
vial
store
c
requir
allow
warm
room
temperatur
dilut
physiolog
salin
produc
stock
solut
filter
flat
filter
portex
hyth
uk
dilut
salin
pyr
infus
three
increment
dose
visit
dose
previous
optim
pilot
studi
dose
infus
min
min
salin
infus
washout
period
next
dose
administ
end
studi
sodium
nitroprussid
infus
min
posit
control
follow
salin
infus
neg
control
valu
mean
sem
measur
mean
standard
error
mean
sem
chemic
reagent
purchas
sigma
pool
uk
unless
otherwis
state
pyr
custom
synthes
glp
standard
use
fmoc
chemistri
solid
phase
support
matrix
puriti
malditof
mass
spectroscopi
rphplc
analysi
peptid
test
steril
demonstr
pyrogen
free
biolog
activ
confirm
use
assay
apelin
peptid
synthes
severn
biotech
kidderminst
uk
pyr
synthes
pyr
shown
mass
spectra
pyr
figur
pyr
figur
alon
produc
signal
mz
respect
incub
pyr
result
signal
masstocharg
ratio
correspond
de
novo
gener
pyr
weak
signal
repres
remain
parent
peptid
figur
contrast
incub
pyr
figur
produc
shorter
apelin
fragment
final
enzym
alon
figur
result
interf
signal
relev
mass
rang
pyr
endogen
apelin
peptid
local
endothelium
endogen
pyr
peptid
detect
human
cardiovascular
tissu
local
endothelium
figur
pyr
like
immunoreact
li
detect
vascular
figur
endocardi
figur
endothelium
identifi
posit
stain
vwf
figur
section
human
cardiomyopathi
heart
express
report
increas
zisman
et
al
goulter
et
al
pyr
li
figur
vwfli
figur
also
coexpress
figur
human
lung
importantli
pyr
li
figur
figur
coloc
figur
pulmonari
blood
vessel
importantli
apelin
reduc
pah
presenc
pyr
investig
section
human
pah
lung
compar
normal
lung
figur
pyr
li
detect
vascular
endothelium
pah
lung
figur
l
pyr
compet
bind
nanomolar
affin
pk
n
lower
parent
molecul
pyr
pk
n
figur
exhibit
compar
affin
pyr
pk
n
wherea
extend
peptid
compet
highest
affin
pk
n
shorter
fragment
compet
specif
bind
wherea
less
effect
compet
respect
signal
assay
pyr
inhibit
forskolinstimul
camp
product
subnanomolar
potenc
pd
n
less
potent
refer
agonist
pyr
pd
n
compar
pd
n
pd
n
time
potent
pyr
ligand
fulli
inhibit
camp
product
figur
retain
nanomolar
potenc
pd
n
wherea
inhibit
incomplet
g
proteinindepend
recruit
assay
pyr
pd
n
pyr
pd
n
pd
n
less
potent
camp
assay
pyr
potent
pyr
interestingli
unlik
shorter
peptid
exhibit
compar
potenc
agonist
camp
assay
pd
n
figur
pd
n
less
potent
pyr
curv
incomplet
similar
assay
intern
assay
pyr
pd
less
potent
pyr
pd
peptid
full
agonist
compar
efficaci
valu
e
max
valu
respect
figur
compar
camp
data
three
endogen
peptid
pyr
refer
agonist
analysi
tabl
demonstr
bia
factor
pyr
indic
compar
pyr
pyr
g
protein
bias
markedli
bias
recruit
assay
pyr
significantli
potent
pyr
p
pyr
incub
p
pyr
incub
p
combin
exhibit
compar
potenc
pyr
p
tabl
therefor
reaction
product
pyr
close
resembl
pyr
pyr
pyr
pd
e
max
n
pd
e
max
n
contract
saphen
vein
compar
subnanomolar
potenc
maximum
respons
figur
data
previous
obtain
pyr
assay
brame
et
al
mous
pace
rv
pyr
produc
concentrationdepend
increas
forc
contract
pd
e
max
cacl
n
figur
compar
isoprenalin
pd
e
max
cacl
n
figur
limit
human
atrial
appendag
strip
avail
test
inotrop
action
pyr
tissu
two
patient
pyr
act
posit
inotrop
subnanomolar
potenc
valu
pd
e
max
cacl
n
anesthet
rat
pyr
n
elicit
dosedepend
decreas
bp
figur
decreas
bp
significantli
differ
p
baselin
dose
nmol
cardiac
paramet
sv
co
pv
vti
alter
pyr
figur
human
volunt
n
pyr
figur
produc
compar
dosedepend
increas
forearm
blood
flow
shown
pyr
brame
et
al
signific
effect
either
peptid
heart
rate
blood
pressur
observ
dose
data
shown
administr
intraven
pyr
n
result
signific
dosedepend
decreas
blood
pressur
rat
vivo
paramet
b
stroke
volum
sv
c
cardiac
output
co
peak
veloc
pv
velocitytim
interv
vti
unaffect
dose
pyr
significantli
differ
baselin
p
p
p
oneway
anova
repeat
measur
compar
baselin
dunnett
multipl
comparison
test
peptid
previous
report
substrat
purifi
human
enzym
vicker
et
al
studi
confirm
wang
et
al
also
catalyz
convers
pyr
predomin
cardiovascular
form
apelin
pyr
vitro
result
unexpect
sinc
pmpf
sequenc
pyr
figur
conform
consensu
sequenc
hydrolysi
prox
prohydrophob
vicker
et
al
support
assay
product
de
novo
metabol
demonstr
compar
potenc
synthet
pyr
tabl
result
consist
studi
report
small
proport
pyr
cleav
pyr
rat
vivo
murza
et
al
previous
demonstr
endotheli
express
apelin
kleinz
davenport
kleinz
et
al
use
antibodi
specif
apelin
isoform
contain
ctermin
phenylalanin
figur
consist
report
other
use
altern
strategi
detect
apelin
infus
pyr
healthi
human
volunt
n
result
dosedepend
increas
forearm
blood
flow
significantli
differ
baselin
p
p
oneway
anova
repeat
measur
compar
baselin
dunnett
multipl
comparison
test
express
also
express
endothelium
donoghu
et
al
ham
et
al
rais
possibl
endotheli
process
pyr
produc
pyr
studi
gener
antibodi
crossreact
apelin
isoform
without
ctermin
phenylalanin
allow
select
identif
pyr
human
heart
lung
pyr
li
specif
local
endothelium
apelin
receptor
also
express
suggest
possibl
autocrin
signal
metabolit
tissu
importantli
human
pah
lung
endotheli
apelin
express
known
reduc
alastalo
et
al
kim
et
al
stain
pyr
detect
biolog
activ
pyr
hydrolysi
assum
inactiv
apelin
peptid
wang
colleagu
recent
report
product
pyr
exhibit
reduc
absent
cardiovascular
action
compar
parent
molecul
wang
et
al
howev
emerg
evid
structur
activ
studi
suggest
ctermin
phenylalanin
critic
residu
apelin
biolog
activ
fan
et
al
medhurst
et
al
hypothesi
compar
pyr
pyr
may
retain
signific
activ
inde
result
show
pyr
nanomolar
affin
nativ
human
apelin
receptor
exhibit
reduct
bind
affin
compar
parent
peptid
consist
previou
studi
ctermin
phenylalanin
pyr
replac
alanin
fan
et
al
medhurst
et
al
remov
iturrioz
et
al
minim
loss
receptor
affin
similarli
substitut
ctermin
phenylalanin
pyr
dphenylalanin
result
decreas
receptor
bind
affin
modest
compar
substitut
residu
known
import
bind
murza
et
al
overal
studi
show
loss
ctermin
phenylalanin
apelin
isoform
significantli
alter
receptor
bind
apelin
receptor
g
coupl
habata
et
al
therefor
next
show
pyr
inhibit
forskolinstimul
camp
potenc
less
pyr
agreement
previou
report
alanin
dphenylalanin
substitut
pyr
medhurst
et
al
murza
et
al
el
messari
et
al
iturrioz
et
al
ceraudo
et
al
therefor
studi
confirm
g
induc
signal
preserv
respons
pyr
receptor
bind
addit
g
proteindepend
signal
activ
apelin
receptor
caus
recruit
receptor
intern
evan
et
al
assay
pyr
behav
full
agonist
human
apelin
receptor
reduct
potenc
compar
pyr
abil
induc
receptor
intern
without
ctermin
phenylalanin
report
fan
et
al
howev
shown
second
group
exhibit
markedli
reduc
potenc
efficaci
recruit
intern
rat
apelin
receptor
iturrioz
et
al
ceraudo
et
al
importantli
compar
pyr
pyr
bias
agonist
g
proteindepend
independ
signal
apelin
modul
vascular
tone
cardiac
contractil
vitro
vivo
japp
et
al
japp
et
al
maguir
et
al
barn
et
al
brame
et
al
therefor
expect
found
pyr
contract
human
saphen
vein
equal
potenc
efficaci
compar
previou
data
pyr
maguir
et
al
brame
et
al
potent
inotrop
mous
pace
right
ventricl
human
pace
atria
next
investig
vivo
action
pyr
anesthet
rat
compar
previous
publish
data
pyr
brame
et
al
metabolit
caus
smaller
signific
drop
blood
pressur
contrast
wang
colleagu
wang
et
al
report
pyr
pyr
show
sustain
effect
blood
pressur
min
administr
mice
vivo
although
peptid
appear
show
initi
compar
reduct
blood
pressur
first
min
experi
interestingli
author
also
show
pyr
rapidli
cleav
vitro
vivo
suggest
cleavag
product
may
contribut
observ
sustain
respons
pyr
might
expect
halflif
cleavag
product
like
short
therefor
respons
infus
pyr
observ
initi
min
experi
agreement
hypothesi
rat
studi
brame
et
al
halflif
pyr
less
min
human
figur
schemat
diagram
show
interact
apelinapelin
receptor
renin
angiotensin
system
new
contribut
studi
shown
red
arrow
ang
angiotensin
apj
apelin
receptor
angiotensin
receptor
type
ma
ma
receptor
less
min
japp
et
al
importantli
firstinman
studi
infus
pyr
result
increas
forearm
blood
flow
magnitud
previous
obtain
pyr
brame
et
al
confirm
metabolit
vasodil
human
vivo
acid
proapelin
deriv
prepropeptid
contain
number
pair
basic
amino
acid
residu
possibl
cleavag
site
endopeptidas
produc
isoform
tatemoto
et
al
habata
et
al
ident
peptidas
remain
unknown
studi
report
direct
cleavag
proapelin
proprotein
convertas
subtilisinkexin
furin
bypass
gener
longer
isoform
shin
et
al
posttransl
modif
result
predomin
apelin
isoform
detect
human
cardiovascular
tissu
plasma
pyr
kleinz
davenport
maguir
et
al
zhen
et
al
put
metabolit
cardiac
peptid
pyr
focu
studi
also
explor
pharmacolog
sever
import
apelin
isoform
better
understand
apelin
structur
activ
relationship
name
minimum
activ
fragment
describ
amino
acid
substitut
studi
propos
consensu
amino
acid
within
import
receptor
bind
activ
narayanan
et
al
ctermin
phenylalanin
adjac
prolin
ntermin
pyroglutam
acid
identifi
import
investig
whether
truncat
peptid
retain
signific
bind
function
activ
hypothesi
like
repres
minimum
activ
fragment
shortest
fragment
contain
identifi
import
amino
acid
result
competit
bind
experi
recruit
assay
support
hypothesi
data
previou
public
show
diminish
g
mediat
signal
calcium
mobil
methionin
posit
remov
medhurst
et
al
zhang
et
al
other
demonstr
activ
without
ntermin
pyroglutam
acid
vivo
pisarenko
et
al
residu
arginin
methionin
indispens
requir
form
crucial
rprl
motif
provid
steric
volum
langelaan
et
al
macaluso
glen
gerbier
et
al
contrast
although
ctermin
phenylalanin
shown
make
specif
contact
within
bind
pocket
apelin
receptor
iturrioz
et
al
experiment
data
suggest
remov
abolish
bind
function
activ
earli
alanin
scan
studi
indic
replac
ctermin
phenylalanin
alanin
abolish
g
signal
calcium
mobil
medhurst
et
al
receptor
intern
fan
et
al
howev
conflict
data
report
suggest
antagonist
apelin
receptor
term
g
signal
pyr
de
mota
et
al
hypotens
effect
lee
et
al
studi
found
resembl
pyr
receptor
bind
cell
base
assay
vasoconstrictor
bioassay
base
result
behav
apelin
agonist
evid
receptor
antagon
despit
unclear
biosynthet
pathway
report
equal
higher
bind
affin
potenc
inhibit
camp
accumul
induc
receptor
intern
compar
pyr
medhurst
et
al
el
messari
et
al
investig
assay
consist
found
higher
bind
affin
higher
potenc
pyr
camp
assay
intriguingli
appear
bias
compar
g
protein
signal
rel
refer
agonist
pyr
suggest
ntermin
extens
may
result
peptid
stabil
differ
conform
apelin
receptor
may
mechan
apelin
receptor
activ
finetun
cellular
level
past
studi
suggest
possibl
link
apelin
receptor
renin
angiotensin
system
exampl
apelin
knockout
mice
show
age
stressassoci
cardiac
contractil
defect
similar
cardiac
phenotyp
knockout
mice
kuba
et
al
apelin
receptor
knockout
mice
sensit
pressor
effect
angiotensin
ii
ishida
et
al
interestingli
express
reduc
apelin
knockout
mice
apelin
upregul
express
indic
apelin
may
reciproc
impact
sato
et
al
receptor
level
apelin
receptor
shown
physic
interact
angiotensin
receptor
type
forc
low
affin
state
reduc
bind
signal
angiotensin
ii
siddique
et
al
reduc
apelin
express
due
heart
failur
angiotensin
ii
administr
restor
blockad
iwanaga
et
al
oppos
effect
angiotensin
ii
shown
health
diseas
heart
failur
atherosclerosi
obesitydiabet
ashley
et
al
gurzu
et
al
iwanaga
et
al
zhong
et
al
chun
et
al
barn
et
al
siddique
et
al
figur
studi
contribut
evid
upregul
diseas
act
pyr
may
result
gener
activ
metabolit
pyr
therefor
compensatori
mainten
apelin
receptor
signal
howev
limit
studi
measur
level
apelin
peptid
plasma
patient
receiv
therapi
would
hypothes
level
pyr
would
elev
pyr
decreas
compar
control
conclus
studi
confirm
cleav
pyr
pyr
demonstr
biolog
activ
pyr
human
apelin
receptor
vitro
cardiovascular
system
rat
human
vivo
result
also
clarifi
shortest
activ
apelin
fragment
agonist
potent
agonist
pyr
therefor
studi
show
report
enhanc
activ
cardiovascular
diseas
significantli
compromis
benefici
effect
apelin
base
therapi
exampl
pah
author
contribut
either
concept
design
work
py
ab
ad
ms
rg
jc
iw
apd
jm
acquir
analyz
data
interpret
data
py
rk
ab
ad
ms
apd
jm
author
agre
account
aspect
work
